microDimensions was founded as a spin-off of the Technische Universität München in 2011. As a provider of software solutions and services for the processing, visualization, and analysis of microscopic image data the company aims to speed up workflows for pathologists, medical laboratories and institutes, pharmaceutical and biotech companies as well as researchers in the field of digital pathology.
microDimensions’ first product, Voloom®, gained lots of attention in the market as it is the first solution for the reconstruction of consecutive histology sections stored as virtual slides. In December 2013, microDimensions closed a financing round with three investment partners (HTGF, Bayern Kapital, and a business angel).
Anyslide was developed and released in 2017, based on our deep understanding of pathological workflows and know-how in digital image processing. This online platform supports pathologist in collaborating on virtual pathology images in research, education, or clinical routine – regardless of how advanced their labs are on the digital journey and no matter which infrastructure is already available to them.
microDimensions has established a strong partner network and collaborates closely with some of the leading manufacturers of digital slide scanning and microscopic software solutions as well as with international distributors in the field of digital microscopy and pathology.
microDimensions provides innovative software solutions and services for the processing, analysis, and visualization of biomedical imagery, in particular on a cellular level. Employees of microDimensions continuously strive to create efficient algorithms fulfilling highest quality standards. A particular focus of the company is to offer digital pathology software that can be integrated into the existing customer workflow seamlessly.
Customers of microDimensions are pathologists and image analysts working with digital slide images for medical research and patient diagnosis. With our products, they are able to create new information extracted from existing images and speed up the laboratory or diagnostic workflow through increased digitization and automation. By providing tools and services for professional online exchange, we help our customers to improve diagnosis and research and to make healthcare more precise and profound.
Our team has a combined 60+ years of experience in the development of sophisticated technologies and software for computer aided diagnosis and microscopic image processing especially in the field of digital pathology. microDimensions has established a biomedical network and partnerships with manufacturers of medical technology and the pharmaceutical industry. Our technical expertise in combination with a strong network of partners such as Bitplane leverages the success of products developed by microDimensions.
Dr. Andreas Keil (CEO)
is in charge of general management, finance and investor relations. Prior to joining microDimensions, Andreas was a post-doctoral fellow in the Radiological Sciences Lab at Stanford University's School of Medicine. He has worked as an intern and research assistant at several divisions of Siemens in Germany and the US as well as France's National Institute for Research in Computer Science and Control. Andreas holds a PhD in Computer Science from Technical University of Munich.
Ralph Gloser (CCO)
leads the sales, marketing, product and business development activities of microDimensions. After graduating from ESB Reutlingen and ESC Reims he went straight into Life Science world and acquired strategic and operational management know-how in the Americas, Europe and Asia. He is a customer-focused entrepreneur who has a successful track record with 20+ years’ progressive business management experience across start-up, mature, turnaround and high growth business operations.
Dr. Marco Feuerstein (CTO)
is co-founder of microDimensions and leads technology development and research. He holds a PhD in Computer Science from Technical University of Munich and was awarded multiple scholarships in Singapore, Taiwan, Japan, and Germany. He worked at several high-tech companies such as BMW and Siemens. During his 2-year postdoctoral fellowship in Japan he was successfully leading a team of researchers working on different aspects of bronchoscopy. He has 20 years of programming experience and 15 years of experience in medical image processing and computer aided diagnosis and surgery. He authored and coauthored more than 35 international peer-reviewed papers and several patent applications.
Dr. Christian Hilz (Chairman)
is Managing Director at TREND-STORE shop creation GmbH. He was CFO of Proteros biostructures GmbH and AutoVision GmbH, a 100% subsidiary of Volkswagen AG, as well as a position as Managing Director at AutoVision Belgium. He also held the position of Managing Director at TUM Tech GmbH, a consulting company focused on technology transfer from Technische Universität München. He received a degree and a subsequent PhD in Business Administration from Ludwig-Maximilians-Universität München.
Prof. Dr. med. Kerstin Amann
is head of the Nephropathology at Friedrich-Alexander-Universität Erlangen-Nürnberg. She studied Medicine at the Ruprecht-Karls-Universität in Heidelberg and was awarded the Bernd-Tersteegen-Preis, the Dieter-Klaus-Förderpreis, the Franz-Volhard-Preis, as well as several congress awards. She gave numerous invited talks at international congresses, such as International Society of Nephrology, European Renal Association, European Society of Cardiology, European Peritoneal Dialysis Society, and European Society of Artificial Organs. Mrs. Amann is member of several international congress advisory committees and of the management team of the Deutsche Gesellschaft für Nephrologie.
Dr. Dirk Kreder, MBA
is founder and CEO of anteris medical GmbH. Anteris develops medical devices for a broad customer portfolio in the biopharma and medical device industries, and brings them to regulatory clearance in Europe and the US. Before building his own company, Dirk held positions of increasing responsibility with pharma and biopharma companies in the US, Switzerland, and Germany, amongst them Novartis, Roche, and Abgenix (now Amgen). Dirk holds a Ph.D. in Immunology and Molecular Biology from University of Stuttgart, an International Executive MBA from the Euro*MBA Consortium, and received post-graduate training certificates from Harvard Business School and the University of California Santa Cruz.
Dr. Adriaan Hart de Ruijter, MBA
is managing director of Cascara Ventures, an early stage life sciences venture fund. He has over twenty-seven years of experience in the life science industry. He founded MSOURCE, the European contract research organization in 1994, which he sold to TÜV SÜD in 2008 (now CROMsource). Since then he ventured into medical data, imaging, oncology and several other therapeutic areas through partnerships and venture capital, building new companies and realizing exits. Adriaan Hart de Ruijter is a specialist in pharmaceutical medicine and holds an MD degree from Leiden University and an MBA from the Rotterdam School of Management.